UroAlert - GU Oncology Weekly

October 02, 2025

Videos

Peer-to-Peer Clinical Conversations

RNA and DNA Biomarkers in Trimodal Therapy for Bladder Cancer - Kent Mouw

Kent Mouw

Ashish Kamat interviews Kent Mouw about biomarkers for muscle-invasive bladder cancer, particularly in bladder preservation strategies.

AI's Role in Prostate Cancer Diagnosis, Imaging, and Pathology - Matthew Cooperberg

Joseph Prijdekker

Matthew Cooperberg discusses artificial intelligence's rapid integration into prostate cancer care.

Beyond the Abstracts

Association of Elevated Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and De Ritis Ratios with Major Complications after Surgery for Renal Cell Carcinoma - Beyond the Abstract

BCL2 Drives Castration Resistance in Castration-Sensitive Prostate Cancer by Orchestrating Reciprocal Crosstalk Between Oncogenic Pathways - Beyond the Abstract

Conference Coverage

SCS AUA 2025: Trial in Progress: PIVOT-006 – a Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate Risk NMIBC

SCS AUA 2025: Penelope: Tissue Penetration of Gemcitabine Phosphate Metabolites Following TAR-200 Administration Versus Standard Intravesical Instillation in Minipigs

SCS AUA 2025: Streamlined, Patient-Centric Design of the Cretostimogene Grenadenorepvec Expanded Access Program in Patients with NMIBC Unresponsive to BCG

SCS AUA 2025: Trials in Progress: BOND-003 Cohort P: A Multi-Institutional, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-Unresponsive NMIBC

SCS AUA 2025: Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk NMIBC

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Management of clinical stage T3/T4 bladder cancer: a review.

Germline homologous recombination repair (gHRR) variants in bladder cancer: Preliminary evidence and clinical implications.

Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.

The association between prior pelvic radiotherapy for cancer and surgical outcomes in patients undergoing radical cystectomy for bladder cancer: An analysis of national surgical quality improvement program targeted cystectomy database.

Analysis of the Fragmentation and Integrity of Urine Cell-Free DNA as Diagnostic and Staging Biomarker for Bladder Cancer.

Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer.

State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer.

Nectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier.

Functional Interrogation of the Impact of ERCC2 Mutations in Bladder Cancer on Cisplatin Sensitivity - Expert Commentary

Detection of Genome-Wide Methylation Changes in Bladder Cancer by Long-Read Sequencing of Urinary DNA - Beyond the Abstract

Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.

Dual Molecular Axis of Resistance and Immunoresponsiveness to BCG in pT1 Non-Muscle Invasive Bladder Cancer: Insights from HER-2, SERBP1, HABP4, and IFN-γ Profiling - Beyond the Abstract

Characterizing pelvic organ descent in women after radical cystectomy: an exploratory analysis.

Shaping the Future of Personalized Therapy in Bladder Cancer Using Artificial Intelligence - Beyond the Abstract

Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic Review - Beyond the Abstract

Attendings versus Supervised Residents: Educational Results and Future Perspective in Transurethral Resection of Bladder Tumors - Beyond the Abstract

Penile & Urethral Cancers

A Rare Genital Concomitant Presentation of Extracavitary Primary Effusion Lymphoma and Squamous Cell Carcinoma.

Evaluating the Evolving Treatment Landscape of Systemic Therapies in Penile Cancer.

Renal Cancer

Biphasic (squamoid) papillary renal cell carcinoma: a distinct molecular and morphologic subtype within the PRCC spectrum.

Ablative techniques in renal tumours for inoperable patients: Step forward in SBRT.

Clinical Practice and Prognostic Molecular Biomarkers in Clear Cell Renal Cell Carcinoma: Latest Advancements.

Cancer-specific Mortality After Radical Nephrectomy and Thrombectomy for Renal Cell Carcinoma with Tumor Thrombus According to Histological Subtypes.

Small renal masses: Where do we stand? An updated analysis of trends and outcomes from the SEER database (2000-2021).

CDCA8 and TROAP as Prognostic Biomarkers of Postoperative Metastatic Progression in Clear Cell Renal Cell Carcinoma.

Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review.

Small Renal Mass Cryoablation: Trifecta Outcomes of a Single-Institution Experience with a 20-Year Follow-Up.

Staging CT chest for cT1a renal masses: Does it change management?

Rising Trends of Aggressive Renal Cell Carcinoma Among Younger Adults: Insights From the National Cancer Database.

Immune-Based Combinations in Intermediate-/Poor-Risk Patients with Non-Clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study - Beyond the Abstract

Prostate Cancer

MiraDx Announces the Commercial Availability of PROSTOX™ ultra for Prediction of Risk of Late Genitourinary Toxicity in Prostate Cancer Patients Considering Radiation Therapy

Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer.

First-Line [177Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer.

Safety of the Combination of External Beam Radiotherapy with 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Tria

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

The Comparative Toxicity of Focal Ablation vs. IMRT for Prostate Cancer.

Detection of Clinically Significant Prostate Cancer Using Micro-Ultrasound Versus MRI/Ultrasound Fusion Biopsy: A Propensity-Weighted Comparative Study.

Diagnostic accuracy of biparametric vs. multiparametric MRI for clinically significant prostate cancer.

Adjustable TransObturator Male System (ATOMS) After Radiotherapy: Is Timing Everything? A Single-Center Experience.

Preclinical Evaluation of [212Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted α-Therapy for Prostate Cancer.

Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study.

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate-Resistant Prostate Cancer.

Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer.

Theranostic Potential of a New 64Cu-Labeled NOTA-R954 Peptide Conjugate for Kinin B1R Expressing Prostate Cancer.

Exploring the Intestinal Microbiota Profile in Prostate Cancer Patients and Healthy Controls.

CYR61 Expression Is Induced by IGF1 and Promotes the Proliferation of Prostate Cancer Cells Through the PI3/AKT Signaling Pathway.

Reappraisal of Neuroendocrine Tumor Classification of the Prostate Gland: Translating Molecular Insights into Clinical Practice.

Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial.

Latest Advancements and Future Directions in Prostate Cancer Surgery: Reducing Invasiveness and Expanding Indications.

Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing.

Application of the STRATCANS Criteria to the MUSIC Prostate Cancer Active Surveillance Cohort: A Step Towards Risk-Stratified Active Surveillance.

The comeback of orchiectomy in advanced prostate cancer- is that feasible?

Addition of androgen-receptor pathway inhibitors to standard of care in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Impaired Mitochondrial Metabolism Is a Critical Cancer Vulnerability for MYC Inhibitors

Multiparametric MRI combined with PSA density as a noninvasive rule-out strategy in active surveillance for prostate cancer.

Extracellular Vesicles in Serum Carry Trop2 Protein as a Potential Molecular Indicator in Prostate Cancer.

Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.

177Lu-vipivotide tetraxetan (PSMA-617) vs cabazitaxel in metastatic castration-resistant prostate cancer: a real-world analysis using the TriNetX database.

Robot-Assisted Salvage Prostatectomy: External Validation of the EAU Selection Criteria and Identification of the Optimal Candidate: A Junior ERUS/YAU Collaborative Study.

Stage-Standardized and Stage-Specific Survival Among Men with Prostate Cancer in the Nordic Countries 2004-16: The NORDCAN Survival Studies - Beyond the Abstract

Treatment of Biochemical Recurrence after Primary Therapy with Curative Intent - Beyond the Abstract

Magnetic Resonance Guided Stereotactic Reirradiation for Locally Recurrent Prostate Cancers: Long-Term Results from a Prospective Registry Study - Beyond the Abstract

Updated Results of MR-Assisted Focal Salvage HDR Prostate Brachytherapy: A Prospective Study - Beyond the Abstract

BRCA2 Reversion Mutation-Independent Resistance to PARP Inhibition Through Impaired DNA Prereplication Complex Function - Beyond the Abstract

Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer - Beyond the Abstract

Upper Tract Tumors

Current Kidney-Preserving Strategies for Upper Tract Urothelial Carcinoma.

Incidence of Low-risk Upper Tract Urothelial Carcinoma in Candidates for Kidney-sparing Surgery.

A structured training curriculum for robot-assisted radical nephroureterectomy: a Delphi consensus study.

Testicular Cancer

MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses.

"We're the silent people in the situation": a qualitative examination of the lived experiences of young partners of men diagnosed with testicular cancer.

Molecular Features and Actionable Gene Targets of Testicular Germ Cell Tumors in a Real-World Setting.

Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC